Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GPR183 | P32249 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781900 | 0.89 | USP30 (0.36) | GPR119USP30SCD5USP2SMN1; SMN2 | |
| SCHEMBL783121 | 0.85 | ESR2 (0.42) | GPR119USP30SCD5USP2SMN1; SMN2 | |
| SCHEMBL781907 | 0.84 | GPR119 (0.37) | GPR119USP30SCD5USP2SMN1; SMN2 | |
| SCHEMBL781918 | 0.80 | FAAH (0.39) | USP30 | |
| SCHEMBL801936 | 0.77 | HPGD (0.35) | SMN1; SMN2 | |
| SCHEMBL30935371 | 0.77 | EGFR (0.43) | USP30EGFRBTKMAPTTP53 | |
| SCHEMBL855880 | 0.75 | RIPK1 (0.47) | GPR119USP30SCD5USP2SMN1; SMN2 | |
| SCHEMBL781904 | 0.74 | GRIA2 (0.40) | GPR119SMN1; SMN2 | |
| SCHEMBL782099 | 0.73 | MAPT (0.39) | SMN1; SMN2MAPTTP53 | |
| SCHEMBL782225 | 0.72 | LMNA (0.47) | GPR119SCD5SMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569285-B2 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071462-A1 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | GABRA1, GRM1, GABRA5 | GPR119 164/4885USP30 2228/4885SCD5 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.